Author:
Sonnenberg Elena,Terjung Birgit
Publisher
Deutscher Arzte-Verlag GmbH
Reference43 articles.
1. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al.: Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol January 2018; 15 (1): 39–49.
2. Neurath MF: Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol August 2019; 20 (8): 970–9.
3. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 29 October 1955; 2 (4947): 1041–8.
4. Rosiou K, Carbonell J, Dolby V, Monfared N, Raine T, Selinger CP: Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study. Aliment Pharmacol Ther August 2022; 56 (3): 501–9.
5. Bei Patienten mit chronisch-entzündlichen Darmerkrankungen (M. Crohn, Colitis ulcerosa) soll eine langfristige systemische Kortikosteroidtherapie als Rezidivprophylaxe nicht durchgeführt werden. Verfügbar unter: https://www.klug-entscheiden.com/empfehlungen/detailansicht?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bnews%5D=218&cHash=d28f9a9b4b82377552970991caf06551 (last accessed on 25 February 2024).